secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266933
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M
--------------------------------------------------------------------------------

- DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.
- Ex-US regulatory clearance obtained; Phase 1 MAD trial in Australia to start H1 2026; splicing data expected 2027.
- Q3 2025 net loss $17.0M; R&D expense $14.6M; G&A expense $4.7M.
- Cash and securities $206.0M as of Sept 30, 2025, supporting pipeline advancement.
- Board appointed Justin Gover (former CEO of GW Pharma, led $7B acquisition by Jazz) in September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/0001193125-25-266933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/dsgn-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer